Ophthalmic suspensions
Patent 5192535 Issued on March 9, 1993. Estimated Expiration Date: 
June 27, 2010. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
June 27, 2010. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent ReferencesOpthalmic solution Sustained release ophthalmic drug dosage Sustained release ophthalmic drug dosage Ophthalmic drug delivery system utilizing thermosetting gels Ocular preparation housing steroid in two different therapeutic forms Bioadhesive compositions and methods of treatment therewith Lacrimal secretion stimulant (lss) Sustained release, comfort formulation for glaucoma therapy Patent #: 4911920 InventorsApplicationNo. 544518 filed on 06/27/1990US Classes:424/78.04, Ophthalmic preparation424/427, Ocular424/428, Bioerrodable, resorbable, or dissolving424/443, Web, sheet or filament bases; compositions of bandages; or dressings with incorporated medicaments424/484, Matrices424/486, Synthetic polymer424/487, Acrylic acid and derivatives514/772.3, Solid synthetic organic polymer514/772.4, Polymer from ethylenic monomers only514/772.6, Carboxylic acid containing monomer514/912, OPHTHALMIC514/913, Glaucoma514/914, Inflammation514/915, Wetting agent514/944, GEL514/953, SHAPED FORMS ADAPTED FOR NONINGESTIBLE USE OTHER THAN SUPPOSITORY TYPE (E.G., FILMS, INSERTS, ETC.)514/954OcularExaminersPrimary: Page, Thurman K.Assistant: Azpuru, Carlos Attorney, Agent or FirmForeign Patent References
International ClassesA61F 002/14A61K 009/64 A61K 009/70 A61K 031/765 AbstractLightly crosslinked polymers, preferably ones prepared by suspension or emulsion polymerizing at least about 90% by weight of a carboxyl-containing monoethylenically unsaturated monomer such as acrylic acid with from about 0.1% to about 5% by weight of a polyfunctional, and preferably difunctional, crosslinking agent such as divinyl glycol (3,4-dihydroxy-1,5-hexadiene), having a particle size of not more than about 50 μm in equivalent spherical diameter, when formulated with an ophthalmic medicament, e.g., fluorometholone, into suspensions in aqueous medium in which the amount of polymer ranges from about 0.1% to about 6.5% by weight, based on the total weight of the aqueous suspension, the pH is from about 3.0 to about 6.5, and the osmotic pressure (osmolality or tonicity) is from about 10 mOsM to about 400 mOsM, provide new topical ophthalmic medicament delivery systems having suitably low viscosities which permit them to be easily administered to the eye in drop form, and hence be comfortably administrable in consistent, accurate dosages. These suspension will rapidly gel in the eye after coming into contact with the eye's tear fluid to a substantially greater viscosity than that of the originally-introduced suspension and thus remain in place for prolonged periods of time to provide sustained release of the ophthalmic medicament.Other References
Field of SearchOcularBioerrodable, resorbable, or dissolving Web, sheet or filament bases; compositions of bandages; or dressings with incorporated medicaments Gelatin Matrices Synthetic polymer Acrylic acid and derivatives Ophthalmic preparation C-O-group (e.g., alcohol, alcoholate, etc.) DOAI OPHTHALMIC Glaucoma Inflammation Wetting agent GEL SHAPED FORMS ADAPTED FOR NONINGESTIBLE USE OTHER THAN SUPPOSITORY TYPE (E.G., FILMS, INSERTS, ETC.) Ocular Carboxylic acid containing monomer From carboxylic acid monomer Carboxylic acid contains ester group Carboxylic acid other than acrylic or methacrylic acid With chalcogen containing monomer, e.g., additional carboxyl monomer, etc. From carboxylic acid ester monomer | |
